Open source anaerobic and temperature-controlled in vitro model enabling real-time release studies with live bacteria

Christfort, Juliane Fjelrad; Polhaus, Chrysillis Judy Magaard; Bondegaard, Pi Westi; Chang, Tien‐Jen; Hwu, En‐Te; Nielsen, Line Hagner; Zór, Kinga; Boisen, Anja

doi:10.1016/j.ohx.2022.e00275

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Birk et al obtained antibiotic micro-containers to treat Pseudomonas aeruginosa infections in oral biofilms [89]. Moreover, the use of microcontainers in topical treatment may lead to a reduction in required doses and the risk of developing resistance [90][91][92].…”

Section: Intraoral Mucoadhesive Systemsmentioning

confidence: 99%

Challenges in Optimizing Nanoplatforms Used for Local and Systemic Delivery in the Oral Cavity

Cocoș,

Dumitriu Buzia,

Tatu

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

In this study, we focused on innovative approaches to improve drug administration in oral pathology, especially by transmucosal and transdermal pathways. These improvements refer to the type of microneedles used (proposing needles in the saw), to the use of certain enhancers such as essential oils (which, besides the amplifier action, also have intrinsic actions on oral health), to associations of active substances with synergistic action, as well as the use of copolymeric membranes, cemented directly on the tooth. We also propose a review of the principles of release at the level of the oral mucosa and of the main release systems used in oral pathology. Controlled failure systems applicable in oral pathology include the following: fast dissolving films, mucoadhesive tablets, hydrogels, intraoral mucoadhesive films, composite wafers, and smart drugs. The novelty elements brought by this paper refer to the possibilities of optimizing the localized drug delivery system in osteoarthritis of the temporomandibular joint, neuropathic pain, oral cancer, periodontitis, and pericoronitis, as well as in maintaining oral health. We would like to mention the possibility of incorporating natural products into the controlled failure systems used in oral pathology, paying special attention to essential oils.

show abstract

Section: Intraoral Mucoadhesive Systemsmentioning

confidence: 99%

Challenges in Optimizing Nanoplatforms Used for Local and Systemic Delivery in the Oral Cavity

Cocoș,

Dumitriu Buzia,

Tatu

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…In the present study, we, therefore, re-evaluated the idea with the hypothesis that targeted delivery of EcN to a permissive intestinal niche could promote colonisation and hereby increase the competition ability against UC-associated E. coli strains. To obtain such targeted delivery, we used a microscale delivery system, denoted microcontainers (Nielsen et al 2016a ), into which powdered drugs (Christfort et al 2020 , Kamguyan et al 2022 , Torp, Kamguyan et al 2022 ) or probiotics (Kamguyan et al 2021 , Christfort, Polhaus et al 2022 ) can be loaded. Microcontainers have been fabricated in various shapes and sizes from 60 to 450 µM (Abid et al 2019 , Dalskov Mosgaard et al 2019 , Christfort et al 2020 , Chang et al 2023 , Petersen et al 2015 ), but in this study, cylindrical devices with an inner diameter of 236 ± 1 µm (mean ± SD) and height of 218 ± 1 µm (mean ± SD) was used.…”

Section: Introductionmentioning

confidence: 99%

Delivery of E. coli Nissle to the mouse gut by mucoadhesive microcontainers does not improve its competitive ability against strains linked to ulcerative colitis

Bondegaard,

Torp,

Guerra

et al. 2023

FEMS Microbiology Letters

Self Cite

View full text Add to dashboard Cite

For patients with ulcerative colitis (UC), administration of the probiotic E. coli Nissle (EcN) holds promise for alleviation of disease symptoms. The mechanisms are unclear, but it has been hypothesised that a capacity of the probiotic to outcompete potentially detrimental UC-associated E. coli strains plays an important role. However, this could previously not be confirmed in a mouse model of competition between EcN and two UC-associated strains, as reported by Petersen et al. 2011. In the present study, we re-evaluated the idea, hypothesising that delivery of EcN by a micro device dosing system (microcontainers), designed for delivery into the intestinal mucus, could support colonisation and confer a competition advantage compared to classical oral dosing. Six groups of mice were pre-colonised with one of two UC-associated E. coli strains followed by oral delivery of EcN, either in capsules containing microcontainers with freeze-dried EcN powder, capsules containing freeze-dried EcN powder, or as a fresh sucrose suspension. Co-colonisation between the probiotic and the disease-associated strains was observed regardless of dosing method, and no competition advantages linked to microcontainer delivery were identified within this setup. Other approaches are thus needed if the competitive capacity of EcN in the gut should be improved.

show abstract

Open source anaerobic and temperature-controlled in vitro model enabling real-time release studies with live bacteria

Cited by 2 publications

References 27 publications

Challenges in Optimizing Nanoplatforms Used for Local and Systemic Delivery in the Oral Cavity

Challenges in Optimizing Nanoplatforms Used for Local and Systemic Delivery in the Oral Cavity

Delivery of E. coli Nissle to the mouse gut by mucoadhesive microcontainers does not improve its competitive ability against strains linked to ulcerative colitis

Contact Info

Product

Resources

About